ARHGEF2 and cancer: The most effective inhibitor, TAT-P5, was found to block GEF-H1-driven epithelial and endothelial cytoskeletal remodeling and malfunction in in vitro disease models for TGFβ1-stimulated fibrosis in primary RPE and LPS-activated processes in primary endothelial cells, as well as cancer cell migration.